Fraiser Kansteiner

2 weeks ago | fiercepharma.com | Fraiser Kansteiner

While the omission of pharmaceuticals from President Donald Trump’s much-anticipated reciprocal tariffs gave the industry a momentary reprieve, renewed threats of drug duties—which have pressured scores of health stocks—suggest any relief is likely short-lived.

2 weeks ago | fiercepharma.com | Fraiser Kansteiner

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire across the globe and make inroads into large markets like Brazil. Now, in a bid to boost its production capacity in Latin America’s most populous country, Novo is plugging 6.4 billion Brazilian reais (roughly $1.09 billion) into an expansion of its manufacturing plant in the Brazilian city of Montes Claros.

2 weeks ago | fiercepharma.com | Fraiser Kansteiner

Less than a year after purchasing private cell therapy company ImmPact Bio to help refresh its ailing CAR-T pipeline, manufacturing considerations have prompted Lyell Immunopharma to cut staff at its new subsidiary and mothball a California facility picked up in the deal. Lyell is laying off 73 employees at ImmPact’s West Hills manufacturing facility in Los Angeles beginning in June, according to a Worker Adjustment and Retraining Notification Act alert filed with the state of California.

2 weeks ago | fiercepharma.com | Fraiser Kansteiner

On the heels of a recent cost-cutting drive that severed much of AmplifyBio’s R&D capacity, the Ohio-based contract manufacturing and research hybrid has hung up its hat for good. Amplify’s decision to close down followed months of work from company leaders, investors and others to “explore and exhaust all investment and acquisition opportunities,” the combination CRO-CDMO explained in a notification pinned to the top of its website.

2 weeks ago | fiercepharma.com | Fraiser Kansteiner

As reports surface detailing the extent of Robert F. Kennedy Jr.’s layoffs at the Department of Health and Human Services, FDA officials are sounding the alarm about their ability to review applications for new drugs moving forward. The 3,500 job cuts recently announced at the FDA, some of which went into effect Tuesday, have already claimed staff essential to the drug review process, Reuters reported Friday, citing both current and former sources at the regulator.